Zensun Science & Technology raised $76M from a group of investors led by SDIC Venture Capital Management, which contributed half of the funding itself.
November 17, 2017 -- Zensun (Shanghai) Science & Technology raised $76 million from a group of investors led by SDIC Venture Capital Management, which contributed half of the funding itself. Zensun’s lead drug is Neucardin™, a novel treatment for chronic heart failure that is aimed at building the heart muscle. Zensun believes the drug, which has completed several Phase II trials in China and the US, will prove to improve cardiac function rather than treating the symptoms of cardiac disease.
